Differential sensory gating functions between smokers and non-smokers among drug-naive first episode schizophrenic patients

Psychiatry Research

Volumn 188, Issue 3, 2011, Pages 327-333

  Chen, Xing shi ^a   Li, Chun bo ^a   Smith, Robert C ^b,c   Xiao, Ze ping ^a   Wang, Ji jun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

Auditory P50 suppression; Schizophrenia; Sensory gating; Smoking

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; CHRONICITY; CIGARETTE SMOKING; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE DURATION; EVOKED AUDITORY RESPONSE; HUMAN; LATENT PERIOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SELF MEDICATION; SENSORY GATING; SENSORY STIMULATION; SMOKING HABIT; STIMULUS RESPONSE;

ACOUSTIC STIMULATION; ADULT; HUMANS; INHIBITION (PSYCHOLOGY); MALE; PSYCHIATRIC STATUS RATING SCALES; REACTION TIME; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SENSORY GATING; SMOKING; STATISTICS AS TOPIC; YOUNG ADULT;

EID: 79960699839     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2010.12.009     Document Type: Article

References (79)

1. Adler L.E., Pachtman E., Franks R.D., Pecevich M., Waldo M.C., Freedman R. Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biological Psychiatry 1982, 17:639-654.
2. Adler L.E., Hoffer L.J., Griffith J., Waldo M.C., Freedman R. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenias. Biological Psychiatry 1992, 32:607-616.
3. Adler L.E., Hoffer L.D., Wiser A., Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenia patients. The American Journal of Psychiatry 1993, 150:1856-1861.
4. Adler L.E., Olincy A., Waldo M., Harris J.G., Griffith J., Stevens K., Flach K., Nagamoto H., Bickford P., Leonard S., Freedman R. Schizophrenia, sensory gating, and nicotinic receptors. Schizophrenia Bulletin 1998, 24:189-202.
5. Adler L.E., Olincy A., Waldo M., Harris J.G., Griffith J., Stevens K., Flach K., Nagamoto H., Bickford P., Leonard S., Freedman R. Schizophrenia, sensory gating, and nicotinic receptors. Schizophrenia Bulletin 1998, 24:189-202.
6. Adler L.E., Olincy A., Cawthra E.M., McRae K.A., Harris J.G., Nagamoto H.T., Waldo M.C., Hall M.H., Bowles A., Woodward L., Ross R.G., Freedman R. Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. The American Journal of Psychiatry 2004, 161:1822-1828.
7. Adler L.E., Olincy A., Cawthra E.M., McRae K.A., Harris J.G., Nagamoto H.T., Waldo M.C., Hall M.H., Bowles A., Woodward L., Ross R.G., Freedman R. Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. The American Journal of Psychiatry 2004, 161:1822-1828.
8. Adler L.E., Cawthra E.M., Donovan K.A., Harris J.G., Nagamoto H.T., Olincy A., Waldo M.C. Improved p50 auditory gating with ondansetron in medicated schizophrenia patients. The American Journal of Psychiatry 2005, 162:386-388.
9. Arango C., Summerfelt A., Buchanan R.W. Olanzapine effects on auditory sensory gating in schizophrenia. The American Journal of Psychiatry 2003, 160:2066-2068.
10. Blumenfeld L., Clementz B. Response to the first stimulus determines reduced auditory evoked response suppression in schizophrenia: single trial analysis using MEG. Clinical Neurophysiology 2001, 112:1650-1659.
11. Boutros N.N., Belger A. Midlatency evoked potentials attenuation and augmentation reflect different aspects of sensory gating. Biological Psychiatry 1999, 45:9717-9722.
12. Boutros N.N., Zouridakis G., Overall J. Replication and extension of P50 findings in schizophrenia. Clinical Electroencephalography 1991, 22:40-45.
13. Braff D.L., Geyer M.A. Sensimotor gating and schizophrenia. Archives of General Psychiatry 1990, 47:181-188.
14. Bramon E., Rabe-Hesketh S., Sham P., Murray R.M., Frangou S. Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophrenia Research 2004, 1:315-329.
15. Brenner C.A., Kieffaber P.D., Clementz B.A., Johannesen J.K., Shekhar A., O'Donnell B.F., Hetrick W.P. Event-related potential abnormalities in schizophrenia: a failure to "gate in" salient information?. Schizophrenia Research 2009, 113:332-338.
16. Brinkman M.J., Stauder J.E. Development and gender in the P50 paradigm. Clinical Neurophysiology 2007, 118:1517-1524.
17. Brockhaus-Dumke A., Schultze-Lutter F., Mueller R., Tendolkar I., Bechdolf A., Pukrop R., Klosterkoetter J., Ruhrmann S. Sensory gating in schizophrenia: P50 and N100 gating in antipsychotic-free subjects at risk, first-episode, and chronic patients. Biological Psychiatry 2008, 64:376-384.
18. Chen X.S., Zhang M.D., Wang H.X., Lou C.Y., Wang J.J., Guo Q., Liu L., Gao C.Y., Liu P., Liu X.W., Duan H.J., Guo F.L., Liang J.H., Chen C., Chen X.W. Sensory gating of patients with first-episode schizophrenia. Zhonghua Yi Xue Za Zhi 2005, 85:3457-3459. (Chinese).
19. Clementz B.A., Geyer M.A., Braff D.L. Multiple site evaluation of P50 suppression among schizophrenia and normal comparison subjects. Schizophrenia Research 1998, 30:71-80.
20. Clementz B.A., Geyer M.A., Braff D.L. Poor P50 suppression among schizophrenia patients and their first-degree biological relatives. The American Journal of Psychiatry 1998, 155:1691-1694.
21. Cooper J.R., Bloom F.E., Roth R.H. The Biochemical Basis of Neuropharmacology 1996, Oxford University Press, Oxford. 7th Edition.
22. Crawford H.J., McClain-Furmanski D., Castagnoli N., Castagnoli K. Enhancement of auditory sensory gating and stimulus-bound gamma band 40Hz oscillations in heavy tobacco smokers. Neuroscience Letters 2002, 317:151-155.
23. Croft R.J., Dimoska A., Gonsalvez C.J., Clarke A.R. Suppression of P50 evoked potential component, schizotypal beliefs and smoking. Psychiatry Research 2004, 128:53-62.
24. de Leon J., Diaz F.J. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophrenia Research 2005, 76:135-157.
25. DeBruin N.M.W.M., Ellenbroek B.A., Van Luijtelaar E.L.J.M., Cools A.R., Stevens K.E. Hippocampal and cortical sensory gating in rats: effects of Quinpirole microinjections in nucleus accumbens core and shell. Neuroscience 2001, 105:169-180.
26. Devrim-Uçok M., Keskin-Ergen H.Y., Uçok A. P50 gating at acute and post-acute phases of first-episode schizophrenia. Progress in Neuropsychopharmacology & Biological Psychiatry 2008, 32:1952-1956.
27. de Wilde O.M., Bour L.J., Dingemans P.M., Koelman J.H., Linszen D.H. Failure to find P50 suppression deficits in young first-episode patients with schizophrenia and clinically unaffected siblings. Schizophrenia Bulletin 2007, 33:1319-1323.
28. Eccles J.C. The Inhibitory Pathways of the Central Nervous System 1969, University Press, Liverpool, England.
29. Erwin R.J., Turetsky B.I., Moberg P., Gur R.C., Gur R.E. P50 abnormalities in schizophrenia: relationship to clinical and neuropsychological indices of attention. Schizophrenia Research 1998, 33:157-167.
30. Fowler J.S., Volkow N.D., Wang G.J., Pappas N., Logan J., Shea C., Alexoff D., MacGregor R., Schlyer D.I., Zezulkova I., Wolf A.P. Brain monoamine oxidase A inhibition in cigarette smokers. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:14065-14069.
31. Franks R.D., Adler L.E., Waldo M.C., Alpert J., Freedman R. Neurophysiological studies of sensory gating in mania: comparison with schizophrenia. Biological Psychiatry 1983, 18:989-1005.
32. Freedman R., Adler L.E., Waldo M.C., Pachtman E., Franks R.D. Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: comparison of medicated and drug-free patients. Biological Psychiatry 1983, 18:537-551.
33. Freedman R., Waldo M.C., Bickford-Weimer P., Nagamoto H. Elementary neuronal dysfunctions in schizophrenia. Schizophrenia Research 1991, 4:233-243.
34. Freedman R., Coon H., Myles-Worsley M., Orr-Urtreger A., Olincy A., Davis A. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:587-592.
35. Freedman R., Leonard S., Gault J.M., Hopkins J., Cloninger C.R., Kaufmann C.A., Tsuang M.T., Farone S.V., Malaspina D., Svrakic D.M., Sanders A., Gejman P. Linkage disequilibrium for schizophrenia at the chromosome 15q13-14 locus of the alpha7-nicotinic acetylcholine receptor subunit gene (CHRNA7). American Journal of Medical Genetics 2001, 105:20-22.
36. Freedman R., Olincy A., Ross R.G., Waldo M.C., Stevens K.E., Adler L.E., Leonard S. The genetics of sensory gating deficits in schizophrenia. Current Psychiatry Reports 2003, 5:155-161.
37. Freedman R., Olincy A., Buchanan R.W., Harris J.G., Gold J.M., Johnson L., Allensworth D., Guzman-Bonilla A., Clement B., Ball M.P., Kutnick J., Pender V., Martin L.F., Stevens K.E., Wagner B.D., Zerbe G.O., Soti F., Kem W.R. Initial phase 2 trial of a nicotinic agonist in schizophrenia. The American Journal of Psychiatry 2008, 165:1040-1047.
38. Gjini K., Arfken C., Boutros N.N. Relationships between sensory "gating out" and sensory "gating in" of auditory evoked potentials in schizophrenia: a pilot study. Schizophrenia Research 2010, 121:139-145.
39. Goff W.R., Williamson P.D., VanGilder J.C., Allison T., Fisher T.C. Neural origins of long latency evoked potentials recorded from the depth and from the cortical surface of the brain in man. Progress in Clinical Neurophysiology 1980, 7:126-145.
40. Goff D.C., Henderson D.C., Amico E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. The American Journal of Psychiatry 1992, 149:1189-1194.
41. Griffith J.M., O'Neill J.E., Petty F., Garver D., Young D., Freedman R. Nicotinic receptor desensitization and sensory gating deficits in schizophrenia. Biological Psychiatry 1998, 44:98-106.
42. Grunwald T., Butros N.N., Pezer N., von Oertzen J., Fernández G., Schaller C., Elger C.E. Neuronal substrates of sensory gating with the human brain. Biological Psychiatry 2003, 53:511-519.
43. Hong X., Chan R.C., Zhuang X., Jiang T., Wan X., Wang J., Xiao B., Zhou H., Jiang L., Weng B. Neuroleptic effects on P50 sensory gating in patients with first-episode never-medicated schizophrenia. Schizophrenia Research 2009, 108:151-157.
44. Judd L.L., McAdams L., Budnick B., Braff D.L. Sensory gating deficits in schizophrenia: new results. The American Journal of Psychiatry 1992, 149:488-493.
45. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987, 13:261-276.
46. Kizkin S., Karlidag R., Ozcan C., Ozisik H.I. Reduced P50 auditory sensory gating response in professional musicians. Brain and Cognition 2006, 61:249-254.
47. Kumari V., Postma P. Nicotine use in schizophrenia: the self medication hypotheses. Neuroscience and Biobehavioral Reviews 2005, 29:1021-1034.
48. Leonard S., Adams C., Breese C.R., Adler L.E., Bickford P., Byerley W., Coon H., Griffith J.M., Miller C., Myles-Worsley M., Nagamoto H.T., Rollins Y., Stevens K.E., Waldo M., Freedman R. Nicotinic receptor function in schizophrenia. Schizophrenia Bulletin 1996, 22:431-445.
49. Leonard S., Mexal S., Freedman R. Smoking, genetics and schizophrenia: evidence for self medication. Journal of Dual Diagnosis 2007, 3:43-59.
50. Levin E.D., Petro A., Caldwell D.P. Nicotine and clozapine actions on pre-pulse inhibition deficits caused by N-methyl-d-aspartate (NMDA) glutamatergic receptor blockade. Progress in Neuropsychopharmacology & Biological Psychiatry 2005, 29:581-586.
51. Light G.A., Braf D.L. Sensory gating deficits in schizophrenia: can we parse the effects of medication, nicotine use, and changes in clinical status?. Clinical Neuroscience Research 2003, 3:47-54.
52. Light G.A., Geyer M.A., Clementz B.A., Cadenhead K.S., Braff D.L. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. The American Journal of Psychiatry 2000, 157:767-771.
53. Luntz-Leybman V., Bickford P., Freedman R. Cholinergic gating of response to auditory stimuli in rat hippocampus. Brain Research 1992, 587:130-136.
54. McEvoy J.P., Brown S. Smoking in first-episode patients with schizophrenia. The American Journal of Psychiatry 1999, 156:1120-1121.
55. Moxon K.A., Gerhardt G.A., Adler L.E. Dopaminergic modulation of the P50 auditory-evoked potential in a computer model of the CA3 region of the hippocampus: its relationship to sensory gating in schizophrenia. Biological Cybernetics 2003, 88:265-275.
56. Olincy A., Young D.A., Freedman R. Increased levels of the nicotine metabolite cotinine in schizophrenia smokers compared to other smokers. Biological Psychiatry 1997, 42:1-5.
57. Olincy A., Harris J.G., Johnson L.L., Pender V., Kongs S., Allensworth D., Ellis J., Zerbe G.O., Leonard S., Stevens K.E., Stevens J.O., Martin L., Adler L.E., Soti F., Kem W.R., Freedman R. Proof-of-concept trial of an α 7 nicotinic agonist in schizophrenia. Archives of General Psychiatry 2006, 63:630-638.
58. Potter D., Summerfelt A., Gold J., Buchanan R.W. Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. Schizophrenia Bulletin 2006, 32:692-700.
59. Rasco L., Skinner R.D., Garcia-Rill E. Effect of age on sensory gating of the sleep state-dependent P1/P50 midlatency auditory evoked potential. Sleep Research Online 2000, 3:97-105.
60. Sacco K.A., Bannon K.L., George T.P. Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders. Journal of Psychopharmacology 2004, 18:457-474.
61. Siegel C., Waldo M., Mizner G., Adler L.E., Freedman R. Deficits in sensory gating in schizophrenic patients and their relatives. Evidence obtained with auditory evoked responses. Archives of General Psychiatry 1984, 41:607-612.
62. Scottish Schizophrenia Research Group Smoking habits and plasma lipid peroxide and vitamin E levels in never-treated first-episode patients with schizophrenia. The British Journal of Psychiatry 2000, 176:290-293.
63. Smith D.A., Boutros N.N., Schwarzkopf S.B. Reliability of P50 auditory event-related potential indices of sensory gating. Psychophysiology 1994, 31:495-502.
64. Smith R.C., Singh A., Infante M., Khandat A., Kloos A. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology 2002, 27:479-497.
65. Strand J.E., Nyback H. Tobacco use in schizophrenia: a study of cotinine concentrations in the saliva of patients and controls. European Psychiatry 2005, 20:50-54.
66. Tang Y.L., Gillespie C.F., Epstein M.P., Mao P.X., Jiang F., Chen Q., Cai Z.J., Mitchell P.B. Gender differences in 542 Chinese inpatients with schizophrenia. Schizophrenia Research 2007, 97:88-96.
67. Thoma R.J., Hanlon F.M., Petropoulos H., Miller G.A., Moses S.N., Smith A., Parks L., Lundy S.L., Sanchez N.M., Jones A., Huang M., Weisend M.P., Cañive J.M. Schizophrenia diagnosis and anterior hippocampal volume make separate contributions to sensory gating. Psychophysiology 2008, 45:926-935.
68. Turetsky B.I., Calkins M.E., Light G.A., Olincy A., Radant A.D., Swerdlow N.R. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophrenia Bulletin 2007, 33:69-94.
69. Venables P. Input dysfunction in schizophrenia. Progress in Experimental Personality Research 1964, 1-47. Academic Press, Orlando, Fla. B.A. Maher (Ed.).
70. Waldo M.C., Cawthra E., Adler L.E., Dubester S., Staunton M., Nagamoto H., Baker N., Madison A., Simon J., Scherzinger A., Drebinga C., Gerhardtb G., Freedman R. Auditory sensory gating, hippocampal volume, and catecholamine metabolism in schizophrenias and their siblings. Schizophrenia Research 1994, 12:93-106.
71. Waldo M.C., Cawthwra E., Adler L.E. Auditory sensory gating, hippocampal volume, and catecholamine metabolism in schizophrenics and their siblings. Schizophrenia Research 1994, 12:93-106.
72. Wan L., Crawford H.J., Boutros N. P50 sensory gating: impact of high vs. low schizotypal personality and smoking status. International Journal of Psychophysiology 2006, 60:1-9.
73. Wan L., Crawford H.J., Boutros N. Early and late auditory sensory gating: moderating influences from schizotypal personality, tobacco smoking status, and acute smoking. Psychiatry Research 2007, 30:11-20.
74. Ward P.B., Hoffer L.D., Liebert B.J., Catts S.V., O'Donnell M., Adler L.E. Replication of a P50 auditory gating deficit in Australian patients with schizophrenia. Psychiatry Research 1996, 64:121-135.
75. Wilson C.L., Babb T.L., Halgren E., Wang M.L., Crandall P.H. Habituation of human limbic neuronal response to sensory stimulation. Experimental Neurology 1984, 7:126-145.
76. Winterer G., Weinberger D.R. Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends in Neurosciences 2004, 27:683-690.
77. Yang Y.K., Nelson L., Kamaraju L., Wilson W., McEvoy J.P. Nicotine decreases bradykinesia-rigidity in haloperidol-treated patients with schizophrenia. Neuropsychopharmacology 2002, 27(4):684-686.
78. Zhang X.Y., Tan Y.L., Zhou D.F., Haile C.N., Wu G.Y., Cao L.Y., Kosten T.A., Kosten T.R. Nicotine dependence, symptoms and oxidative stress in male patients with schizophrenia. Neuropsychopharmacology 2007, 32:2020-2024.
79. Zhang X.Y., Li C.B., Li M., Zheng Y.L., Zhang C.X., Yan Q.Z., Liu W.Z., Kang Y.M., Wang F., Chen da.C., Xiu M.H., Kosten T.R. Smoking initiation and schizophrenia: a replication study in a Chinese Han population. Schizophrenia Research 2010, 119:110-114.